Drugs / EuPCV15
last change Feb 2021 re-read 2 minutes ago

EuPCV15

Vaccine

Developed for
pneumococcal infection
Investigated by
EuBiologics Co.,Ltd

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04830358 May → Aug 2020 pneumococcal infection EuBiologics Co.,Ltd Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EuPCV15 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830358
Modality Vaccine “15-valent Pneumococcal conjugate vaccineNCT04830358
Route Intramuscular “will be administered intramuscularly at Day 0.” NCT04830358